These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 25855300)

  • 21. Potent
    Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
    Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
    J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.
    Mikell I; Stamatatos L
    PLoS One; 2012; 7(11):e49610. PubMed ID: 23152926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.
    Cavacini LA; Samore MH; Gambertoglio J; Jackson B; Duval M; Wisnewski A; Hammer S; Koziel C; Trapnell C; Posner MR
    AIDS Res Hum Retroviruses; 1998 May; 14(7):545-50. PubMed ID: 9591708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
    Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
    Liao HX; Lynch R; Zhou T; Gao F; Alam SM; Boyd SD; Fire AZ; Roskin KM; Schramm CA; Zhang Z; Zhu J; Shapiro L; ; Mullikin JC; Gnanakaran S; Hraber P; Wiehe K; Kelsoe G; Yang G; Xia SM; Montefiori DC; Parks R; Lloyd KE; Scearce RM; Soderberg KA; Cohen M; Kamanga G; Louder MK; Tran LM; Chen Y; Cai F; Chen S; Moquin S; Du X; Joyce MG; Srivatsan S; Zhang B; Zheng A; Shaw GM; Hahn BH; Kepler TB; Korber BT; Kwong PD; Mascola JR; Haynes BF
    Nature; 2013 Apr; 496(7446):469-76. PubMed ID: 23552890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Walsh SR; Seaman MS
    Front Immunol; 2021; 12():712122. PubMed ID: 34354713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-mediated prevention and treatment of HIV-1 infection.
    Gruell H; Klein F
    Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly Neutralizing Antibodies for HIV Eradication.
    Stephenson KE; Barouch DH
    Curr HIV/AIDS Rep; 2016 Feb; 13(1):31-7. PubMed ID: 26841901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
    Stephenson KE; Julg B; Tan CS; Zash R; Walsh SR; Rolle CP; Monczor AN; Lupo S; Gelderblom HC; Ansel JL; Kanjilal DG; Maxfield LF; Nkolola J; Borducchi EN; Abbink P; Liu J; Peter L; Chandrashekar A; Nityanandam R; Lin Z; Setaro A; Sapiente J; Chen Z; Sunner L; Cassidy T; Bennett C; Sato A; Mayer B; Perelson AS; deCamp A; Priddy FH; Wagh K; Giorgi EE; Yates NL; Arduino RC; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2021 Oct; 27(10):1718-1724. PubMed ID: 34621054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
    Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
    Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
    Ledgerwood JE; Coates EE; Yamshchikov G; Saunders JG; Holman L; Enama ME; DeZure A; Lynch RM; Gordon I; Plummer S; Hendel CS; Pegu A; Conan-Cibotti M; Sitar S; Bailer RT; Narpala S; McDermott A; Louder M; O'Dell S; Mohan S; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Mascola JR; Graham BS;
    Clin Exp Immunol; 2015 Dec; 182(3):289-301. PubMed ID: 26332605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
    Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
    J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
    Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
    J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.